Trial intelligence / Profile preview

Bevacizumab in Post-acute Sequelae of COVID-19

NCT07089719Phase 2

Key facts

Status: Not yet recruiting
Start: Oct 2025
Primary completion: Jan 2028
Countries: 1
Sponsor: Assistance publique - Hôpitaux de Paris
Modality: Monoclonal Antibodies

Drugs: bevacizumab
Conditions: post acute COVID-19 syndrome

Overview

Phase 2, open-label, single-arm trial of bevacizumab in post acute COVID-19 syndrome, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of patients with 10% increase of impaired DLCO at 3 months. Planned start Oct 2025; status: not yet recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Bevacizumab
Experimental arm receiving Bevacizumab

Who it enrols

Adult patients with documented COVID-19 infection > 3 months prior, presenting with Long COVID suspicion, significant dyspnea (mMRC > 2), and impaired DLCO (< 75%). Exclusion criteria include acute COVID-19, recent pulmonary embolism, active cancer, uncontrolled hypertension, and severe renal impairment.

Endpoints

Primary

Rate of patients with 10% increase of impaired DLCO3 months

Secondary

Proportion of patients with recovery of clinical symptoms7 months
Proportion of patients with recovery of psychological, cognitive, and autonomic functions7 months
Proportion of patients with improvement of other parameter than DLCO explored by Pulmonary Function Test7 months
Modification of DLCO2 months
Circulating angiogenic biomarkers levels7 months
Number of side effects related to bevacizumab7 months
Number of patients with hospitalization or medical consultation7 months

Beyond the preview

Go deeper on NCT07089719.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07089719.